论文部分内容阅读
目的 :追踪研究HA加中剂量阿糖胞苷 (ID -Ara-C)方案对急性髓系白血病 (AML)缓解后的疗效。方法 :1 4例AML患者常规诱导达完全缓解后 ,用HA -IDAra-C方案进行缓解后治疗。结果 :完全缓解存活 9例 ,5年长期无复发生存率为 36%。结论 :本方案疗程短、副作用少、复发率低 ,是急性髓系白血病缓解后较理想的化疗方案
OBJECTIVE: To study the curative effect of HA combined with mid-dose cytarabine (ID-Ara-C) on acute myeloid leukemia (AML). Methods: A total of 14 AML patients were treated with HA-IDAra-C regimen after conventional induction of complete remission. Results: Completely relieved the survival of 9 cases, 5-year long-term recurrence-free survival rate was 36%. Conclusion: The short course of treatment, less side effects, low recurrence rate, the acute myeloid leukemia is more ideal chemotherapy regimen